{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-003309","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2023-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.407590+00:00","generated_at":"2026-06-18T07:17:59.869274+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Olema reports FY2022 net loss of $104.8M, restructures to focus on OP-1250 Phase 3","bullets":["Net loss of $104.8M for FY2022, vs $71.1M in FY2021.","Cash and securities $204.4M at Dec 31, 2022, expected to fund operations into 2025.","Workforce reduced by ~25% to focus on late-stage development of OP-1250; CBO leaving, CRO stepping down from role.","Initiating first pivotal Phase 3 trial of OP-1250 in 2H 2023 for ER+/HER2- metastatic breast cancer."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-003309","json":"https://secwatch.observer/filing/0001558370-23-003309.json","markdown":"https://secwatch.observer/filing/0001558370-23-003309.md","text":"https://secwatch.observer/filing/0001558370-23-003309.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/0001558370-23-003309-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/olma-20230309x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T07:17:59.869274+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c644371843821a1158ff9ece5947e52fc7fe954b","claim":"Olema Pharmaceuticals, Inc. reported the quarter ended December 31, 2022 results: net income $26.2 million.","evidence_excerpt":"Net loss was $26.2 million and $104.8 million for the quarter and year ended December 31, 2022, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/0001558370-23-003309-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Net income","value":"$26.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"d5adef17d71a5b4e71f0e683d10bf53967d0b7cb","claim":"Olema Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: net income $104.8 million.","evidence_excerpt":"Net loss was $26.2 million and $104.8 million for the quarter and year ended December 31, 2022, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750284/000155837023003309/0001558370-23-003309-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$104.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}